Literature DB >> 14750170

Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity.

Carla De Giovanni1, Lorena Landuzzi, Giordano Nicoletti, Annalisa Astolfi, Stefania Croci, Massimo Micaroni, Patrizia Nanni, Pier-Luigi Lollini.   

Abstract

APC10.1 is a new intestinal cell line derived from ApcMin/+ mice that retains both the heterozygous Apc genotype and a nonactivated Wnt signaling pathway and displays an early neoplastic phenotype. Although tumorigenic both in immunodepressed and in immunocompetent syngeneic mice, it requires a high cell dose and a long latency. Its epithelial/intestinal origin is shown, in a gene expression profile, by the expression of epithelial transcripts (such as cytokeratin and laminin isoforms) and of developmental regulatory genes (such as Tcf-4, Hnf3beta, p21, Ihh, Hes1) necessary for, or involved in, the maintenance of intestinal stem cells. The lack of activation of the Wnt cascade in APC10.1 cells is shown both by the expression profile of Wnt target genes and by the standard TCF reporter assay. APC10.1 cell line is a novel in vitro model that can contribute to a better understanding of the clinical evolution of familial adenomatous polyposis and to finding of new prophylactic and therapeutic approaches. Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750170     DOI: 10.1002/ijc.11690

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3',4',5'-trimethoxyflavonol, a quercetin analogue.

Authors:  Lynne M Howells; Robert G Britton; Marco Mazzoletti; Peter Greaves; Massimo Broggini; Karen Brown; William P Steward; Andreas J Gescher; Stewart Sale
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-13

2.  Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous.

Authors:  I Asante; D Chui; H Pei; E Zhou; C De Giovanni; D Conti; S Louie
Journal:  J Nutr Biochem       Date:  2019-03-12       Impact factor: 6.048

3.  Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer.

Authors:  Suniti Misra; Shibnath Ghatak; Alok Vyas; Paul O'Brien; Roger R Markwald; Madhukar Khetmalas; Vincent C Hascall; James B McCarthy; Nikos K Karamanos; Markku I Tammi; Raija H Tammi; Glenn D Prestwitch; Subhash Padhye
Journal:  Med Chem Res       Date:  2014-08-01       Impact factor: 1.965

4.  Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE.

Authors:  Suniti Misra; Vincent C Hascall; Carla De Giovanni; Roger R Markwald; Shibnath Ghatak
Journal:  J Biol Chem       Date:  2009-02-26       Impact factor: 5.157

5.  Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.

Authors:  Suniti Misra; Shibnath Ghatak; Neha Patil; Prasad Dandawate; Vinita Ambike; Shreelekha Adsule; Deepak Unni; K Venkateswara Swamy; Subhash Padhye
Journal:  Bioorg Med Chem       Date:  2013-02-27       Impact factor: 3.641

6.  FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells.

Authors:  Shibnath Ghatak; Vincent C Hascall; Roger R Markwald; Suniti Misra
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

7.  Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.

Authors:  Hong Cai; Edwina Scott; Abeer Kholghi; Catherine Andreadi; Alessandro Rufini; Ankur Karmokar; Robert G Britton; Emma Horner-Glister; Peter Greaves; Dhafer Jawad; Mark James; Lynne Howells; Ted Ognibene; Michael Malfatti; Christopher Goldring; Neil Kitteringham; Joanne Walsh; Maria Viskaduraki; Kevin West; Andrew Miller; David Hemingway; William P Steward; Andreas J Gescher; Karen Brown
Journal:  Sci Transl Med       Date:  2015-07-29       Impact factor: 17.956

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.